UCSF

FDA funds UCSF-Stanford CERSI

The U.S. Food and Drug Administration has awarded the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (UCSF-Stanford CERSI) a five-year grant with up to $25 million in funding.

UCSF-Stanford CERSI brings together a world-class team of scientists from two outstanding academic institutions, with partners at the FDA, to spur new approaches and technology to enhance the FDA’s ability to evaluate and approve new medical products. The center also develops educational and research programs and fosters collaborations between scientists, faculty, students, and postdoctoral researchers at the FDA, UC San Francisco, and Stanford University.

The center is led by Kathy Giacomini, PhD, a faculty member in the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine, and Russ Altman, MD, PhD, a professor of bioengineering, genetics, and medicine at Stanford University. It was launched in 2014.

“This new funding is a strong vote of confidence from the FDA that we are on the right path in developing new models and methods for moving drugs and other medical products such as devices and cell-based therapies from the laboratory to clinical trials — not only more efficiently, but with greater confidence that they will be safe and effective,” Giacomini said.

More

FDA Funds UCSF-Stanford Center on Regulatory Science


About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.